We have succesfully finished clinical part of phase II study with patients suffered from diabetes type II.
The aim of the study was to assess safety and efficacy of oral administration of IMP (different doses for each arm including placebo) accompanied to standard treatment, once daily for 14 consecutive days. 80 patients in total were enrolled. No drug related serious adverse events were recorded.
On May 25, 2018, the European Union will begin to enforce more strict privacy rules under the General Data Protection Regulation (GDPR), so we have introduced new Privacy Policy.
In "Scientific Publications" tab you can find an interesting, new article about update of EMA guideline on strategies to identify and mitigate risks for first-in-human clinical trials